-transparent.png){kind=logo}
Enhancement of (AS X Aug)F1 pancreatic islet allograft survival in diabetic AS rats was achieved by treating the recipient with a course of antidonor antiserum. Their survival in both untreated and treated recipients was compared with the survival of transplanted heart, kidney, and skin allografts similarly treated. The islet allografts in the untreated group were rejected by a mean of 3.2 days whereas the other allografts were rejected by a mean of 8.3 days. In the enhanced group all of the kidney allografts, 7 of 11 heart allografts, and 4 of 10 islet allografts had a prolonged survival, whereas none of the skin allografts had a prolonged survival. Islet allografts are thus more susceptible to rejection than other tissues, but their survival can be prolonged using specific immunosuppression. The reasons for the increased susceptibility to rejection are discussed.
J R Nash, and
M Peters, and
P R Bell
April 1973,
The British journal of surgery,
J R Nash, and
M Peters, and
P R Bell
March 1973,
Transplantation proceedings,
J R Nash, and
M Peters, and
P R Bell
April 1982,
Transplantation,
J R Nash, and
M Peters, and
P R Bell
December 1968,
Science (New York, N.Y.),
J R Nash, and
M Peters, and
P R Bell
February 1995,
Transplantation proceedings,
J R Nash, and
M Peters, and
P R Bell
February 1971,
Transplantation,
J R Nash, and
M Peters, and
P R Bell
May 1970,
Circulation,
J R Nash, and
M Peters, and
P R Bell
March 1979,
Lancet (London, England),
J R Nash, and
M Peters, and
P R Bell
November 1973,
Transplantation,
J R Nash, and
M Peters, and
P R Bell
January 1983,
Archivum immunologiae et therapiae experimentalis,
